A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 4, 2012, Pages 591-601

  Bender, Brendan C ^a,b   Schaedeli Stark, Franziska ^c   Koch, Reinhold ^c   Joshi, Amita ^a   Chu, Yu Waye ^a   Rugo, Hope ^d   Krop, Ian E ^e   Girish, Sandhya ^a   Friberg, Lena E ^b   Gupta, Manish ^a,f  

^a GENENTECH INC   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cumulative TCP; Population pharmacokinetic pharmacodynamic model; Semimechanistic; T DM1; Thrombocytopenia; Trastuzumab emtansine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB EMTANSINE;

ARTICLE; BREAST METASTASIS; COMPUTER PROGRAM; DISEASE MODEL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG TOLERABILITY; HUMAN; INCIDENCE; MATHEMATICAL MODEL; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOTOXINS; MAYTANSINE; MODELS, BIOLOGICAL; PLATELET COUNT; RECEPTOR, ERBB-2; THROMBOCYTOPENIA;

EID: 84867571080     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1934-7     Document Type: Article

References (24)

1. Lewis Phillips GD, Li G, Dugger DL et al (2008) Targeting HER2-positive breast cancer with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290. doi:10.1158/0008-5472.CAN-08-1776
2. Krop IE, Beeram M, Modi S et al (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704. doi:10.1200/JCO.2009.26. 2071
3. Burris HA III, Rugo H, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405. doi:10.1200/JCO.2010.29.5865
4. Krop I, LoRusso P, Miller KD et al (2010) A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2? metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Presented at European Society for Medical Oncology Congress, October 8-12, Milan, Italy (abstract 277O)
5. Gupta M, LoRusso PM, Wang B et al (2011) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2- targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol. doi:10.1177/009127 0011403742
6. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721. doi:10.1200/JCO.2002.02.140
7. Friberg LE, Karlsson MO (2003) Mechanistic models for myelosuppression. Invest New Drugs 21:183-194
8. van Kesteren C, Zandvliet AS, Karlsson MO et al (2005) Semiphysiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 23:225-234
9. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD (2006) Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57:427-435. doi:10.1007/s00280-005-0035-2
10. Joerger M, Huitema AD, Richel DJ et al (2007) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13:6410-6418. doi:10.1158/1078-0432. CCR-07-0064
11. Schmitt A, Gladieff L, Laffont C et al (2010) Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol 28:4568-4574. doi: 10.1200/JCO.2010.29.3597
12. Gupta P, Friberg LE, Karlsson MO, Krishnaswami S, French J (2010) A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J Clin Pharmacol 50:679-687. doi:10.1177/0091270009346060
13. Beal SL, Boeckman AJ, Sheiner LB (1992)NONMEMusers guide, part IV. Regents of California, San Francisco. ftp://nonmem. iconplc.com/Public/ nonmem720/guides/iv.pdf. Accessed 16 Dec 2011
14. Khandelwal A, Harling K, Jonsson EN, Hooker A, Karlsson M (2011) A fast method for testing covariates in population PK/PD models. AAPSJ 13:464-472. doi:10.1208/s12248-011-9289-2
15. Hurvitz SA, Dirix L, Kocsis J et al (2011) Trastuzumab emtansine (T-DM1) versus trastuzumab ? docetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). Presented at European Multidisciplinary Cancer Congress, September 23-27, Stockholm, Sweden (abstract 5001)
16. Perry MC, McKinney MF (2008) Chemotherapeutic agents: trastuzumab (herceptin). In: Perry MC (ed) The chemotherapy source book, 4th edn. Lippincott Williams & Wilkins, Philadelphia, p 629
17. Blum RH, Kahlert T (1978) Maytansine: a phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep 62:435-438
18. Blum RH, Wittenberg BK, Canellos GP et al (1978) A therapeutic trial of maytansine. Cancer Clin Trials 1:113-117
19. Rodon J, Garrison M, Hammond LA et al (2008) Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol 62:911-919. doi:10.1007/s00280-007-0672-8
20. Tolcher AW, Ochoa L, Hammond LA et al (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21:211-222. doi:10.1200/JCO. 2003.05.137
21. Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26:2147-2154. doi:10.1200/JCO.2007.15.0532
22. O'Shaughnessy JA, Venzon DJ, Gossard M et al (1995) A phase I study of sequential versus concurrent interleukin-3 and granulocyte- macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood 86:2913-2921
23. Maze R, Moritz T, Williams DA (1994) Increased survival and multilineage hematopoietic protection from delayed and severe myelosuppressive effects of a nitrosourea with recombinant interleukin-11. Cancer Res 54:4947-4951
24. National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer.gov/protoc oldevelopment/electronic- applications/docs/ctcaev3.pdf. Accessed 20 June 2011